Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis

Arthritis Rheumatol. 2017 Jul;69(7):1480-1494. doi: 10.1002/art.40099. Epub 2017 Jun 12.

Abstract

Objective: Systemic-onset juvenile idiopathic arthritis (JIA) is speculated to follow a biphasic course, with an initial systemic disease phase driven by innate immune mechanisms and interleukin-1β (IL-1β) as a key cytokine and a second chronic arthritic phase that may be dominated by adaptive immunity and cytokines such as IL-17A. Although a recent mouse model points to a critical role of IL-17-expressing γ/δ T cells in disease pathology, in humans, both the prevalence of IL-17 and the role of IL-17-producing cells are still unclear.

Methods: Serum samples from systemic JIA patients and healthy pediatric controls were analyzed for the levels of IL-17A and related cytokines. Whole blood samples were studied for cellular expression of IL-17 and interferon-γ (IFNγ). CD4+ and γ/δ T cells isolated from the patients and controls were assayed for cytokine secretion in different culture systems.

Results: IL-17A was prevalent in sera from patients with active systemic JIA, while both ex vivo and in vitro experiments revealed that γ/δ T cells overexpressed this cytokine. This was not seen with CD4+ T cells, which expressed strikingly low levels of IFNγ. Therapeutic IL-1 blockade was associated with partial normalization of both cytokine expression phenotypes. Furthermore, culturing healthy donor γ/δ T cells in serum from systemic JIA patients or in medium spiked with IL-1β, IL-18, and S100A12 induced IL-17 overexpression at levels similar to those observed in the patients' cells.

Conclusion: A systemic JIA cytokine environment may prime γ/δ T cells in particular for IL-17A overexpression. Thus, our observations in systemic JIA patients strongly support a pathophysiologic role of these cells, as proposed by the recent murine model.

MeSH terms

  • Adaptive Immunity / immunology
  • Adolescent
  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Juvenile / drug therapy
  • Arthritis, Juvenile / immunology*
  • CD4-Positive T-Lymphocytes / immunology
  • Case-Control Studies
  • Chemokine CXCL10 / immunology
  • Chemokine CXCL9 / immunology
  • Child
  • Child, Preschool
  • Cytokines / immunology
  • Female
  • Humans
  • Immunity, Innate / immunology
  • Interferon-gamma / immunology
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Interleukin-17 / immunology*
  • Interleukin-18 / immunology
  • Interleukin-18 / pharmacology
  • Interleukin-1beta / immunology
  • Interleukin-1beta / pharmacology
  • Interleukin-23 Subunit p19 / immunology
  • Interleukin-6 / immunology
  • Male
  • Receptors, Antigen, T-Cell, gamma-delta / metabolism
  • S100A12 Protein / immunology
  • S100A12 Protein / pharmacology
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / metabolism
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • CXCL10 protein, human
  • CXCL9 protein, human
  • Chemokine CXCL10
  • Chemokine CXCL9
  • Cytokines
  • IL17A protein, human
  • IL1B protein, human
  • IL23A protein, human
  • IL6 protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-17
  • Interleukin-18
  • Interleukin-1beta
  • Interleukin-23 Subunit p19
  • Interleukin-6
  • Receptors, Antigen, T-Cell, gamma-delta
  • S100A12 Protein
  • canakinumab
  • Interferon-gamma